Cellnovo Reaches First Insulin Cartridge Industrialization Milestone

Regulatory News:

Cellnovo Group (Paris:CLNV) ("Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces that its first industrialisation milestone with Flex has been reached. This is consistent with the manufacturing transfer plan, announced last year, that will bring an increase in the production capacity of Cellnovo’s diabetes management system in the second part of 2016.

Cellnovo began transferring the manufacturing of its disposable insulin cartridges to Flex in Q3 2015 and is benefitting from Flex’s industry-leading experience in automation and manufacturing of medical devices.

Flex has commenced automated manufacturing of the first key sub assembly. This first sub assembly has been sent to Cellnovo to be built into the disposable insulin cartridges at the Company’s facilities and will bring initial increases in production capacity as part of its industrialisation programme.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: "The manufacture of the first sub assembly by Flex is a key milestone in securing a wider roll-out of the Cellnovo system to patients. We look forward to capitalising on the increased capacity that this partnership will deliver and beginning to satisfy the high demand for our products."

John Gethin, Chief Operating Officer at Cellnovo, commented: "We are pleased with the high quality of this first sub assembly from Flex. This demonstrates that our partnership with Flex, and indeed the overall industrialisation of disposable insulin cartridges for the Cellnovo system, is progressing smoothly and is on track.”

Paul Humphries, President of High Reliability Solutions at Flex, added: "Flex is proud to be working alongside Cellnovo, a leading innovator in the growing segment of insulin patch pumps. Flex has the skills and expertise to assist Cellnovo as it looks to scale production and meet the demands of its growing customer base.”

------

In the coming months, Cellnovo will participate in the following investor events:

• Portzamparc Small Caps PEA PME Seminar, April 4, Paris
• European 'Smallcap Event', April 11-12, Paris

About Cellnovo (Euronext: CLNV)
An international commercial medical technology company, Cellnovo markets the first mobile, connected all-in-one diabetes management system, a disruptive technology enhancing daily disease management for Type 1 diabetes patients. Cellnovo’s device currently addresses the $2.2 billion insulin pump market and the Company is reviewing the potential for the device to serve other markets. Cellnovo is currently marketing the device in the UK, France and The Netherlands and has a clearly defined commercial and manufacturing strategy supported by strategic partners Air Liquide and Flextronics. Cellnovo is headquartered in Paris, France, with product development facilities in Wales, UK. For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System
Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin patch pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV

View source version on businesswire.com: http://www.businesswire.com/news/home/20160224005921/en/